The Geneva Talks and Putin’s Inner Circle
The Geneva Talks and Putin’s Inner Circle
The turmoil in Ukraine
The turmoil in Ukraine
Coerced into Sex by Using Threat of Tax Penalty
Coerced into Sex by Using Threat of Tax Penalty
Proposed 2015 Budget Would Increase Taxes by $1.4 Trillion over the Next Decade
Proposed 2015 Budget Would Increase Taxes by $1.4 Trillion over the Ne...
Job Listings

Pill to Treat Low Sexual Desire in Women Rejected by U.S. Regulators

 

Sprout Pharmaceuticals, Inc., which is based in Raleigh, North Carolina, is seeking approval of the therapy known as Flibanserin, as an option for women whose low libido causes stress in their lives. The medicine, a pill, Flibanserin, which would be used to treat low sexual desire in women, was rejected by U.S. regulators, a decision that has been appealed by the drug’s maker in a bid to make it the first product for the disorder on the market.

 

About 43 percent of women experience some sort of sexual dysfunction and one in 10 women have low desire with accompanying distress.



Get JD Journal in Your Mail
Subscribe to our FREE daily news alerts and get the latest updates on the most happening events in the legal, business, and celebrity world. You also get your daily dose of humor and entertainment!!


 

Bloomberg reports that according to Sprout, Flibanserin, if approved, would treat a sexual disorder known as female hypoactive sexual desire disorder, which is low libido that causes stress.

 

The treatments for women’s sexual dysfunction have lagged behind those for men in the 15 years since Pfizer Inc. (PFE)’s Viagra was approved for erectile dysfunction. Pfizer gave up studying Viagra for women in 2004. Treatment for men has since grown into a $4.4 billion market in 2012, according to data compiled by Bloomberg. The FDA identified female sexual dysfunction as one of the conditions the agency has selected as part of an effort to stress the perspective of patients in drug development.

 

Reported as a unanimous decision, an 11-person Food and Drug Administration committee voted against approval of Flibanserin on 18 June. US regulators ruled the controversial drug was little better than placebo for women with low libido.

 

Committee members reported to US media that they were unconvinced the drug had clinically meaningful benefits as a treatment for hypoactive sexual desire disorder in women. There were also other concerns about Flibanserin’s significant side effects and interactions with other drugs.

 

 

 

Image Credit: time.com, smh.com.au

Did you like this? Share it:
Pill to Treat Low Sexual Desire in Women Rejected by U.S. Regulators by

Tagged: , , , , ,

Jaan Posted by on December 11, 2013. Filed under Home,Legal News. You can follow any responses to this entry through the RSS 2.0. You can skip to the end and leave a response. Pinging is currently not allowed.
  • Sara Reed

    Thank you for this article.
    While it is unfortunate that there continue to be challenges around developing solutions for female sexual dysfunction, it is a positive sign that there is greater awareness and understanding that just like men, women have sexual issues that require medical treatment.

    In our work treating female sexual dysfunction at the Medical Center for Female Sexuality in NY, we often meet women who have been suffering from sexual dysfunction for years. They feel alienated from their partners and may even be living like roommates. Fortunately there is treatment out there that can transform relationships but for many women, reaching out for help is a big challenge.

    With more articles like these, women don’t need to feel alone in their suffering.